MDS/MPN Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting mds/mpn clinical trials across 5 countries. Studies span Phase 2, Phase 1, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Berlin, Germany, Chemnitz, Germany. Updated daily from ClinicalTrials.gov.


MDS/MPN Trials at a Glance

8 actively recruiting trials for mds/mpn are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Beijing, Berlin, and Chemnitz. Lead sponsors running mds/mpn studies include Jubilant Therapeutics Inc., Jubilant Therapeutics, Inc., and Benjamin Tomlinson.

Browse mds/mpn trials by phase

Treatments under study

About MDS/MPN Clinical Trials

Looking for clinical trials for MDS/MPN? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MDS/MPN trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MDS/MPN clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)Essential Thrombocythemia, ET
Jubilant Therapeutics Inc.30 enrolled7 locationsNCT07612280
Recruiting
Early Phase 1

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Myelodysplastic SyndromesMDS/MPN Crossover Syndromes
Benjamin Tomlinson20 enrolled1 locationNCT04187703
Recruiting
Phase 1Phase 2

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

MDS/MPN
Michael Savona94 enrolled4 locationsNCT04061421
Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Primary myelofibrosis (PMF)Myeloproliferative DisordersMyelofibrosis+49 more
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting

Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

MDSMDS/MPN
University of Leipzig60 enrolled11 locationsNCT05582902
Recruiting
Phase 2

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.

Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)
Jubilant Therapeutics, Inc.30 enrolled3 locationsACTRN12624000478516
Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute LeukemiaMDSMDS/MPN+1 more
Peking University People's Hospital300 enrolled1 locationNCT06211166
Recruiting
Phase 2

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

MDS/MPN
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT05817955